TREATMENT OF HUMAN PROSTATE TUMORS PC-3 AND TSU-PR1 WITH STANDARD ANDINVESTIGATIONAL AGENTS IN SCID MICE

Both the PC-3 and the TSU-PR1 prostate tumor models were found to be s atisfactory for chemotherapeutic investigations in ICR-SCID mice. The 30 to 60 mg fragments implanted took in all mice (as judged by 100% ta kes in the controls of all experiments as well as the passage mice). T he tumor volume doubling time was 4.0 days for PC-3 and 2.5 days for T SU-PR1. Nine agents were evaluated IV against early stage subcutaneous PC-3 tumors, with Nano-piposulfan being the only agent highly active (4.9 log kill). Three other agents were moderately active: Taxol(l.5 l og kill), Cryptophycin-8 (1.6 log kill), Vinblastine (1.0 log kill). F ive agents were inactive: VP-16, Adriamycin, CisDDPt, 5-FUra, and Cycl ophosphamide. Ten agents were evaluated IV against early stage subcuta neous TSU-PR1 tumors. Three agents were highly active, producing > 6 l og kill and cures: Taxol (5/5 cures), Cryptophycin-8 (5/5 cures), Vinb lastine (2/4 cures). Two other agents were moderately active: Nano-pip osulfan (1.2 log kill), and Cyclophosphamide (1.1 log kill). Five agen ts were inactive: VP-16, Adriamycin, CisDDPt, 5-FUra, and BCNU. In par t, activity was determined by the ability of the SCID mice to tolerate meaningful dosages of the agents. Agents producing granulocyte toxici ty (e.g., Adriamycin) were poorly tolerated and appeared less active t han expected. Vinblastine, producing little or no granulocyte toxicity was very well tolerated and appeared to be more active than expected.